Skip to main content

Table 1 Details of included studies and baseline characteristics of patients in warfarin group and DOACs group

From: Warfarin versus direct oral anticoagulants for treating left ventricular thrombus: a systematic review and meta-analysis

Authors Year Region Study design Study period Sample size (n) Age (years) Males (%)
      Warfarin DOAC Warfarin DOAC Warfarin DOAC
Bass et al 2019 United States Retrospective Sept 2012 – Oct 2018 769 180 70.9 69.4 63 65.6
Daher et al 2020 France Retrospective Jan 2010 – Aug 2019 42 17 63 62.4 61 57
Jaidka et al 2018 Canada Retrospective Not specified 37 12 75 75 61.3 57
Robinson et al 2020 United States Retrospective Oct 2013 – Mar 2019 236 121 72 77.7 58.2 58
Jones et al 2020 United Kingdom Observational Not specified 60 41 85 80.4 60.8 58.7
Yunis et al 2020 United States Retrospective Jan 2014 – April 2019 200 64 NR NR NR NR
Ali et al 2020 United States Retrospective Jan 2012 – Jan 2019 60 32 58 59 81.6 81.3
Iqbal et al 2020 United Kingdom Retrospective Dec 2012 – June 2018 62 22 89 91 62 62
Hypertension (%) Diabetes (%) Smokers (%) STEMI (%) Assessment of Thrombus resolution Type of DOAC used in the study Follow-up duration Primary end-point
Warfarin DOAC Warfarin DOAC Warfarin DOAC Warfarin DOAC  
NR NR NR NR NR NR 57.6 42.8 NR Not specified Not specified Incidence of thromboembolic stroke in patients receiving DOACs compared to warfarin.
40.5 59 21.4 12 59.5 59 74 88 TTE Apixaban
Rivaroxaban
Dabigatran
Not specified Response to DOACs and VKAs
48.6 16.7 18.9 8.3 35 50 100 100 TTE Not specified Not specified Treatment and 6-month outcomes (embolic events, bleeding, and thrombus resolution).
75 71 39 29.8 NR NR 62.7 54.5 TTE Apixaban
Rivaroxaban
Dabigatran
351 days Risk of stroke or systemic embolization.
36.4 60.5 16.7 18.4 33.3 21 86.7 87.8 TTE or CMR Apixaban
Rivaroxaban
Edoxaban
2.2 year Left ventricular thrombus resolution.
NR NR NR NR NR NR NR NR Not specified Not specified 2 years Survival and freedom from bleeding and from stroke and systemic embolism.
NR NR 30 37.5 62 53 NR NR TTE Not specified 1 year Stroke or systemic embolism and thrombus resolution.
29 41 31 86 50 45 89 82 CMR (initially) & TTE (follow-up) Apixaban
Rivaroxaban
Dabigatran
3 years Thromboembolic events and bleeding.
  1. Abbreviations; CMR: Cardiac magnetic resonance; DOAC: Direct oral anticoagulant; NR: Not recorded; TTE: Transthoracic echocardiogram; STEMI: ST-segment elevation myocardial infarction